Project Grant R01GM163338
- Federal Grant Award Summary The University of California, Irvine received a $384,527 Project Grant from the National Institute of General Medical Sciences under the Biomedical Research and Research Training program (CFDA 93.859), effective September 1, 2025, through August 31, 2030. This award funds research to decipher the interactome and biological functions of disordered microproteins—a recently identified class of proteins composed of fewer than 100-150 amino acids encoded by small open...
- Federal Grant Award Summary The University of California, Irvine received a $1.32 million Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective September 15, 2025 through August 31, 2029. This project delivers advanced research and development services to overcome fundamental speed limitations in label-free, single-molecule biosensing applications. The core deliverable is a...
- Federal Grant Award Summary The University of California, Irvine received a $138,489 Project Grant from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) awarded on September 20, 2025, with a completion date of September 19, 2027. The award supports research and development of a methyl arginine targeting chimera (MARTAc) for the lysosomal degradation of intracellular proteins. This project addresses critical limitations of current proteolysis-targeting...
- Federal Grant Award Summary The National Institute of General Medical Sciences awarded UC Riverside a $396,886 Project Grant on March 15, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop enabling technology for characterizing human proteoforms—the active molecular species in cells that include not only genetically encoded protein sequences but also post-translational modifications, alternative splice variants, and other chemical alterations. The research...
- Federal Project Grant Award Summary The University of California, Irvine received a $487,953 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), awarded on March 15, 2026, with a completion date of January 31, 2031. This five-year award supports fundamental research to advance mechanistic understanding of nitrogenase, an enzyme that catalyzes the reduction of atmospheric dinitrogen to ammonia...
- Federal Project Grant Award Summary The University of California, Irvine received a $380,540 Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective September 1, 2025, through June 30, 2030. This award supports investigator-initiated research investigating epigenetic regulation mechanisms in human embryonic stem cell (hESC) lineage specification. The research program will examine...
- Federal Grant Award Summary The National Institute of General Medical Sciences (NIGMS) awarded University of California, Irvine a $1.89 million Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) effective September 1, 2025, through August 31, 2029. The research initiative focuses on developing molecular lanterns—ultra-small ribonucleic acid (RNA) tags that assemble split luciferases—to enable real-time visualization and tracking of multiple RNA transcripts...
- Federal Grant Award Summary The National Institute of General Medical Sciences (NIGMS) awarded a $399,391 Project Grant to the Regents of the University of California at Riverside on May 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859). The project, titled "Molecular Modeling and Theoretical Characterization of Protein Dynamics and Ligand Binding," focuses on developing and applying advanced molecular dynamics (MD) simulation techniques to enhance...
- Federal Project Grant Award Summary The University of California, Irvine received a $493,884 Project Grant from the National Institute of General Medical Sciences under the Biomedical Research and Research Training program (CFDA 93.859) awarded June 1, 2026, through May 31, 2031. Under the direction of Dr. Abraham Lee, this award funds the development and advancement of the Arrayed-Droplet Optical Projection Tomography (ADOPT) platform, a microfluidic technology designed to rapidly acquire and...
- Federal Project Grant Award Summary The National Institute of General Medical Sciences (NIGMS) awarded the University of California, Davis $390,881 on April 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to support a five-year research project extending through March 31, 2031. The award funds fundamental research aimed at decoding the mechanisms and regulatory networks of plant U-box/ring ubiquitin ligase complexes under biotic stress conditions. This research...
The University of California, Irvine received a $448,510 Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective May 1, 2026 through January 31, 2030. This technology development grant supports research into targeted protein degradation utilizing RPN-13, a ubiquitin receptor on the proteasome complex. The research team will develop and expand upon bifunctional molecules designed to degrade proteins of interest by positioning them in close proximity to the proteasome entrance through RPN-13 binding, independent of E3 ligase-mediated ubiquitination. This novel degrader approach aims to create broader therapeutic applicability for treating protein accumulation diseases and various cancer types by circumventing the limitations of existing proteasome inhibitors and proteolysis targeting chimera (PROTAC) technologies. The deliverables from this award will include the advancement of a new class of degrader molecules that leverage the non-essential ubiquitin receptor RPN-13, which is highly expressed in diseased and stressed cells. By eliminating dependence on ubiquitination pathways, these RPN-13-mediated degraders are expected to provide more broadly applicable therapeutic options for oncogenic protein degradation and cellular death induction in cancer-dependent cells. Research will be conducted at UCI's facilities in Irvine, California, contributing to the fundamental scientific understanding necessary for advancing disease diagnosis, treatment, and prevention strategies.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $448.5k | 4/24/26 |